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Introduction
The last 15 years has seen the growth of a new and global healthcare industry based on human proteins produced in genetically engineered cells with an estimated current market value of ~£30 billion a year. There is now an opportunity to replicate this growth in the new industry of regenerative medicine. The next healthcare revolution will apply regenerative medicines, creating biological therapies or substitutes for the replacement or restoration of tissue function lost through failure or disease. However, whilst science has revealed the potential (ref) , and early products have shown the power of such therapies (ref) , there is now a need for the long term supply of human pluripotent stem cells (PSCs) in sufficient numbers to create reproducible and cost effective therapeutic products. Since human cells are known to develop both genetic and epigenetic instability over many passages, as well as loss of functionality 7 , there is a defined need for technologies that will allow the maximal expansion of each cell line for cryobanking at low passage numbers that will enable larger scale healthcare applications. The scale-up techniques to be developed for PSC's are analogous to those already developed for biopharmaceutical production using mammalian cells at large scales but there are a number of unique challenges that need to be addressed not least of which is that it is the cell that is now the product rather than the proteins that they express.
Human PSCs are adherent, dependent on attachment to either a feeder layer of cells or an extracellular matrix substitute and thus, until recently, have been cultured manually in planar, culture systems (T flasks). Although successful automation of these manual hESC culture processes, using for example the CompacT SelecT (The Automation Partnership) or the Cell host (Hamilton Robotics) , has been demonstrated {{379 Thomas,R.J. 2009; 86 Terstegge,S. 2007 ;}} and may be suitable for the cGMP production of smaller quantities of cells for autologous therapies, they are limited ultimately by the necessity of a large footprint within a facility as well as the need for highly trained operators. Additionally, such automated systems often use wasteful quantities of expensive growth media and are only linearly scalable i.e. by adding more vessels or culture platforms, rather than increasing vessel size geometrically.
Now that reports have started to emerge of the successful larger scale culture of PSC's in conventional stirred tank systems using either microcarriers as surfaces for cell attachment (see Table 1 ) or by growing them as suspension aggregates (see Table 2 ) the aim here is to critically review the progress that has been made in the area of suspension culture of PSC's in the last few years. Further we present a detailed analysis of the viability of these methods for realising the end-goal of larger-scale production of therapeutic materials from human pluripotent cells.
Conventional T flask Culture
The ability of PSCs to self-renew and differentiate into specific cell types are key characteristics of the final cell as a product, that must be retained regardless of the method of culture or passaging. In addition, genetic or epigenetic instability, which is known to be associated with long-term culture of hPSC's {{105 Allegrucci,C.
2007;}} and can lead to tumourogenicity must also be avoided. When mouse and human ESC's were first derived and propagated it was found that they were not only adherent, but in order to retain pluripotency they had to be grown on feeder layers {{117 Table 1 . FGF is still a very expensive component of the culture medium, therefore, for larger scales its use should be minimised as far as possible. Significantly, all of the studies in Table 1. have taken place over short timescales with limited passages (typically five or fewer).
Thus, the ability to cultivate cells over a period which would be able to create a clinically-relevant number of cells is, as yet, unproven, with this system. The work performed by Serra et al {{609 Serra,M. 2010;}} has taken the first step in this process, being the first report of successful cultivation of hESC within a fullyinstrumented stirred-tank reactor. This has enabled tight control over the dissolved oxygen within the bioreactor, and subsequent adjustment to investigate the effect of hypoxic conditions.
There is currently a great deal of conflicting data regarding the effect of hypoxia on except where the cells were allowed a larger than normal inter passage interval. One major difference, which is unsurprising, is the large reduction in growth potential as a result of hypoxic conditions. All of the studies which have investigated hypoxia as a method of maintaining pluripotency have reported a 75% reduction in cell density when compared to that for normoxic cultures.
Due to the lack of a cell wall mammalian cells are vulnerable to changes in osmolarity and have long been perceived to be 'shear' sensitive i.e., they are physically damaged by the rotating impeller used in conventional bioreactors. However, it is now recognised that this early concern for 'shear' sensitivity was excessive and the majority of industrial processes for protein production use mammalian cells in free suspension stirred tank bioreactors especially on the large scale (Nienow). Indeed work has shown that cells are much more likely to be damaged by the action of bursting bubbles (for aeration) at the liquid free surface than by the action of fluid shear rates or stresses generated by impellers (Oh et al., 1992) . This damage via the action of bursting bubbles can be easily eliminated by the addition of antifoaming agents such as Pluronic F68 to the culture medium (Nienow, 2006) . The same may apply to the culture of stem cells however, since it is now the cell that is the product rather than the proteins that they produce the situation remains unclear. Indeed it is known (Wang and Thampatty 2008) that mechanical forces, including tension, gravity, hydrostatic pressure, compression, and so called 'shear stress', play an important role in human development. In particular they influence extracellular matrix (ECM) gene expression, ECM protein production, and expression of inflammatory mediators of many mechanically sensitive adult cell types e.g. fibroblasts,
chondrocytes and endothelial cells. Therefore careful studies will need to be conducted that can accurately assess the effect of the fluid mechanical stresses that exist in conventional stirred tank bioreactors before any detrimental effects on the successful bioprocessing of stem cells can be fully discounted.
Recently, it has also become viable to grow hPSC's as clumps or aggregates in suspension, without microcarriers (Table 2. ). This method has the considerable attraction of obviating the need for removal of cells from microcarriers which has received very little attention to date as there in no comparable need and therefore no Therefore in order to fully understand the role of Y-27632 further studies will be needed perhaps using a number of apoptosis detection assays in parallel.
Although the same concentration of Y-27632 (10 µM) was used in each study, exposure times vary considerably; with one reports continuous exposure {{612
Olmer,R. 2010;}}, whilst others report that periodic feeding of the medium with Y-27632 to be detrimental to growth, hence suggesting that shorter exposure times;
ranging from 1 h pre-passage -30 mins post-passage -48 h post-passage would be beneficial.
All of the work that is described here is performed using colony culture prior to the suspension phase. These colonies are manually or enzymatically removed from their substrate (usually with collagenase) and subsequently dissociated into single-cells Based on laboratory experience cultivating pluripotent cells, and literature estimations of production capacity and demand, it is possible to define the conditions that are necessary for production through automated platforms, or stirred-tank methods. In adherent cultures, the output of manufacturing methods is contingent on the total surface area available within a single reactor (whether automated system, or microcarrier-based stirred-tank).
The principle of hPSC growth within an automated T flask based system has already been demonstrated using the Compact Select (The Automation Partnership TAP) (Thomas et al). As such, the model which has been applied here is the larger capacity instrument, from the same company, the Select. The total surface area available for cell growth within a Select is 31580 cm 2 (based on 182 T175 flasks), as such, this is assumed to be the capacity of the system. Based on the manufacturer's instructions (GE Healthcare, ??) for Cytodex microcarriers, the surface area available for cell growth is limited to 88,000 cm 2 per litre. Assuming a liquid volume within the stirredtank of 10,000 L allows a capacity of 8.8 x 10 8 cm 2 .
Whilst From laboratory experiments in standard T flasks, hPSC's can routinely achieve densities of 1.6 x 10 5 cells.cm -2 without reduction in quality, defining the benchmark for this value for both microcarrier and automated planar culture. Throughout this analysis, the primary disease model that has been used is cardiomyocyte replacement for acute cardiovascular disease. Mummery et al suggest that an infarcted heart may require up to 10 9 functional cardiomyocytes, in order to replace tissue which has died during an ischaemic episode. The two remaining variables to be considered are; differentiation efficiency and production efficiency. In any other process, these would be considered together to comprise an overall production efficiency, however, in this case, it is important to highlight what is expected of the differentiation step of the process in order to realise the potential of these cells. Production efficiency has been assumed how? to be 90% (this is far higher than from a pharmaceutical process especially when you consider separation efficiencies) throughout, which, although lower than King et al, is a satisfactory estimate based on the complexity of the process involved. The relatively large volume within this type of flask would likely lead to heat and mass transfer deficiencies, resulting in intra-and inter-flask heterogeneity. The
Hyperflask also exchanges the problem of insufficient surface area for excessive medium use, because the 10-fold higher surface area requires a similar increase in medium volume.
Conclusions and Future Perspectives
Something in hear about timing throw it over the wall etc…Something about defining the problem…. This feasibility study demonstrates that current low differentiation efficiencies are a major hurdle to the exploitation of hPSCs as a source of cells for human therapy.
Research is ongoing in this area and it is expected that these will increase. In addition, more effort needs to be put into developing potential purification technologies specific to these cell therapies in order that manufacturing can be as efficient as possible. Streamlined purification processes are particularly important given that purification accounts for 80 % of the production cost of a biopharmaceutical. Throughout the development of these new processes for expansion and purification of hPSCs, the quality of the cell is paramount and must be maintained in contrast to traditional mammalian cell culture for recombinant biologics. Total Number of TAP Selects (number.yr Assuming differentiation efficiency of 25 % and 6-step production process with each stage having a 90 % yield
